TY - JOUR
T1 - Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers
T2 - A multi-methods approach
AU - Lee, Cheryl T.
AU - Mohamed, Nihal E.
AU - Pisipati, Sailaja
AU - Shah, Qainat N.
AU - Agarwal, Piyush K.
AU - Downs, Tracy M.
AU - Droller, Michael
AU - Gilbert, Scott M.
AU - Goltz, Heather H.
AU - Hall, Simon J.
AU - Hendawi, Mohamed
AU - Hoffman-Censits, Jean
AU - O'Donnell, Michael
AU - Kaag, Matthew
AU - Karsh, Lawrence I.
AU - Kassouf, Wassim
AU - Quale, Diane Z.
AU - Sagalowsky, Arthur
AU - Steinberg, Gary D.
AU - Latini, David M.
N1 - Funding Information:
This study was funded by Bladder Cancer Advocacy Network (BCAN). BCAN is a national advocacy organization committed to supporting patients and families affected by bladder cancer as well as advancing research in the field. Funds were used to assist with data collection, data analyses, and support a research coordinator.
Publisher Copyright:
© 2020 The Author(s).
PY - 2020/7/24
Y1 - 2020/7/24
N2 - Background, context and purpose: In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a mixed-methods approach, this study describes the iterative development, acceptability and feasibility of BC specific SCP (BC-SCP) in clinical settings. Methods: In Phase I, we developed the BC-SCP. In Phase II, we conducted four focus groups with 19 patients and 15 providers to examine its acceptability and usability challenges. Data analyses using the Atlas.ti program, informed refinement of the BC-SCP. In Phase III, we conducted feasibility testing of the refined BC-SCP with 18 providers from 12 health-centers. An encounter survey was completed after each assessment to examine the feasibility of the BC-SCP. Chi-square and Fisher Exact tests were used for comparative analyses. Results: During phase I, we observed high patient and provider acceptability of the BC-SCP and substantial engagement in improving its content, design, and structure. In Phase II, providers completed 59 BC-SCPs. Mean time for BC-SCP completion was 12.3 min. Providers reported that BC-SCP content was clear, did not hamper clinic flow and was readily completed with easy-to-access information. Comparative analyses to examine differences in SCP completion time by patient clinico-demographic characteristics and provider type revealed no significant differences. Conclusions: Our BC-SCP has clinical relevance, and can be used in an active practice setting. However, considerable progress will be necessary to achieve implementation of and sharing the BC-SCP with patients and care providers, particularly within the electronic medical record. In summary, BC-SCPs are essential to improve the follow up care of BC survivors. Clinical resources are required to ensure appropriate implementation of BC-SCPs. Trial registration: Study HUM00056082.
AB - Background, context and purpose: In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a mixed-methods approach, this study describes the iterative development, acceptability and feasibility of BC specific SCP (BC-SCP) in clinical settings. Methods: In Phase I, we developed the BC-SCP. In Phase II, we conducted four focus groups with 19 patients and 15 providers to examine its acceptability and usability challenges. Data analyses using the Atlas.ti program, informed refinement of the BC-SCP. In Phase III, we conducted feasibility testing of the refined BC-SCP with 18 providers from 12 health-centers. An encounter survey was completed after each assessment to examine the feasibility of the BC-SCP. Chi-square and Fisher Exact tests were used for comparative analyses. Results: During phase I, we observed high patient and provider acceptability of the BC-SCP and substantial engagement in improving its content, design, and structure. In Phase II, providers completed 59 BC-SCPs. Mean time for BC-SCP completion was 12.3 min. Providers reported that BC-SCP content was clear, did not hamper clinic flow and was readily completed with easy-to-access information. Comparative analyses to examine differences in SCP completion time by patient clinico-demographic characteristics and provider type revealed no significant differences. Conclusions: Our BC-SCP has clinical relevance, and can be used in an active practice setting. However, considerable progress will be necessary to achieve implementation of and sharing the BC-SCP with patients and care providers, particularly within the electronic medical record. In summary, BC-SCPs are essential to improve the follow up care of BC survivors. Clinical resources are required to ensure appropriate implementation of BC-SCPs. Trial registration: Study HUM00056082.
KW - Bladder Cancer specific survivorship care plan
KW - Care providers
KW - Focus groups
KW - Muscle invasive bladder Cancer
KW - Non-muscle invasive bladder Cancer
KW - Survivorship care plan
UR - http://www.scopus.com/inward/record.url?scp=85088680090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088680090&partnerID=8YFLogxK
U2 - 10.1186/s12913-020-05533-7
DO - 10.1186/s12913-020-05533-7
M3 - Article
C2 - 32709234
AN - SCOPUS:85088680090
SN - 1472-6963
VL - 20
JO - BMC Health Services Research
JF - BMC Health Services Research
IS - 1
M1 - 686
ER -